Related Experiment Video
Updated: Nov 11, 2025
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Prognostic Significance of CD30 in Transformed Mycosis Fungoides
Antonio Travaglino1, Daniela Russo1, Silvia Varricchio1
1Department of Advanced Biomedical Sciences, Pathology Section Naples, Italy.
Objectives:
Several studies suggested that CD30 expression is a favorable prognostic marker in transformed mycosis fungoides (tMF). However, evidence in this field is still unclear. This systematic review and meta-analysis aimed to evaluate the prognostic significance of CD30 in tMF.
Methods:
Electronic databases were searched from their inception to June 2020 for all studies assessing the prognostic value of CD30 in tMF. Pooled hazard ratio (HR) for death was calculated; a P value less than .05 was considered significant. Inconsistency index (I2) was used to assess statistical heterogeneity among studies.
Results:
Seven studies with 323 patients were included. CD30 expression in tMF was significantly associated with a decreased hazard of death both on univariate (HR, 0.459; 95% confidence interval [CI], 0.319-0.660; P < .001) and multivariate analysis (HR, 0.503; 95% CI, 0.345-0.734; P < .001), and the statistical heterogeneity among studies was null in all analyses (I2 = 0%).
Conclusions:
tMF cases with CD30 expression in large cells have a hazard of death two times lower than CD30-negative cases.
Insights
CD30 expression in transformed mycosis fungoides (tMF) is a favorable prognostic marker. Patients with CD30-positive tMF have a significantly lower hazard of death compared to CD30-negative cases.
Area of Science:
- Dermatology
- Oncology
- Pathology
Background:
- Transformed mycosis fungoides (tMF) is an advanced stage of cutaneous T-cell lymphoma.
- The prognostic significance of CD30 expression in tMF remains debated.
- Accurate prognostic markers are crucial for guiding treatment decisions in tMF.
Purpose of the Study:
- To systematically review and meta-analyze existing evidence.
- To evaluate the prognostic significance of CD30 expression in tMF.
- To clarify the association between CD30 and patient outcomes.
Main Methods:
- Systematic literature search of electronic databases up to June 2020.
- Inclusion of studies assessing the prognostic value of CD30 in tMF.
- Calculation of pooled hazard ratios (HR) for mortality using univariate and multivariate analyses.
Main Results:
- Seven studies comprising 323 patients were included in the meta-analysis.
- CD30 expression in tMF was significantly associated with a reduced hazard of death (HR 0.459 univariate, HR 0.503 multivariate).
- No statistical heterogeneity was observed among the included studies (I2 = 0%).
Conclusions:
- CD30 expression in large cells of tMF indicates a favorable prognosis.
- Cases of tMF with CD30 expression have a two-fold lower hazard of death compared to CD30-negative cases.
- CD30 is a reliable positive prognostic marker in transformed mycosis fungoides.
More Related Videos
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019